SCHEMBL2937052

SCHEMBL2937052

COCOc1ccc(C2=Cc3ccc(OCOC)cc3OC2)cc1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RARA P10276 3/20 0.40
RARG P13631 3/20 0.40
RARB P10826 2/20 0.40
ALOX5 P09917 1/20 0.40
NR1H4 Q96RI1 1/20 0.37
FYN P06241 4/20 0.35
PTGS2 P35354 1/20 0.34
PTPN1 P18031 1/20 0.33
ROR1 Q01973 1/20 0.33
MAOB P27338 5/20 0.33
CYP11B1 P15538 1/20 0.33
CYP11B2 P19099 1/20 0.33
MAOA P21397 1/20 0.33
MEN1 O00255 1/20 0.32
ALDH1A1 P00352 1/20 0.32
MAPT P10636 1/20 0.32
TSHR P16473 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2742798 0.91 MAPT (0.39) RARARARGRARBALOX5NR1H4
SCHEMBL4556762 0.83 CYP2D6 (0.42) RARARARGRARBALOX5ALDH1A1
SCHEMBL12946430 0.80 ALOX5 (0.43) RARARARGRARBALOX5NR1H4
SCHEMBL2328053 0.78 ALOX5 (0.41) ALOX5NR1H4PTGS2ROR1MAOB
SCHEMBL949460 0.77 MAOB (0.51) ALOX5MAOBMAOAALDH1A1MAPT
SCHEMBL4549088 0.77 MAOB (0.35) ALOX5NR1H4MAOBMAOAALDH1A1
SCHEMBL4556779 0.77 THRA (0.37) ALOX5NR1H4PTPN1ROR1MAOB
SCHEMBL1962780 0.75 MAOB (0.51) ALOX5MAOBMAOAALDH1A1MAPT
SCHEMBL952469 0.73 NR1H4 (0.54) RARARARGRARBALOX5NR1H4
SCHEMBL2071380 0.72 RARA (0.48) RARARARGRARBALOX5NR1H4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103641808-B The enantioselective hydrogenation method of chromene GIRINDUS AMERICA INC. (US) 2016-04-20 CN disclosed
CN-103755675-B The enantioselective hydrogenation method of chromene GIRINDUS AMERICA INC. (US) 2015-11-18 CN disclosed
EP-1919887-B1 METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES GIRINDUS AMERICA INC (US) 2015-02-18 EP disclosed
CN-101535286-B Process for the enantioselective hydrogenation of chromenes GIRINDUS AMERICA INC 2014-05-07 CN disclosed
US-8716497-B2 Method for enantioselective hydrogenation of chromenes CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2014-05-06 US disclosed
US-8716497-B2 Method for enantioselective hydrogenation of chromenes CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2014-05-06 US disclosed
CN-103755675-A Method for enantioselective hydrogenation of chromenes GIRINDUS AMERICA INC 2014-04-30 CN disclosed
CN-103641808-A Method for enantioselective hydrogenation of chromenes GIRINDUS AMERICA INC 2014-03-19 CN disclosed
US-20130116450-A1 METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES GIRINDUS AMERICA, INC. (US) 2013-05-09 US disclosed
US-20130116450-A1 METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES GIRINDUS AMERICA, INC. (US) 2013-05-09 US disclosed
US-20100069653-A1 METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES Children hospital medical center (US) 2010-03-18 US disclosed
CN-101535286-A Process for the enantioselective hydrogenation of chromenes GIRINDUS AMERICA INC (US) 2009-09-16 CN disclosed
US-7528267-B2 Method for enantioselective hydrogenation of chromenes GIRINDUS AMERICA, INC. (US) 2009-05-05 US disclosed
US-7528267-B2 Method for enantioselective hydrogenation of chromenes GIRINDUS AMERICA, INC. (US) 2009-05-05 US disclosed
US-7528267-B2 Method for enantioselective hydrogenation of chromenes GIRINDUS AMERICA, INC. (US) 2009-05-05 US disclosed
EP-1919887-A2 METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES Girindus America, Inc. (US) 2008-05-14 EP disclosed
WO-2007016423-A2 METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES GIRINDUS AMERICA INC. (US) 2007-02-08 WO disclosed
US-20070027329-A1 Method for enantioselective hydrogenation of chromenes AUSIO PHARMACEUTICALS, LLC 2007-02-01 US disclosed
US-20070027329-A1 Method for enantioselective hydrogenation of chromenes AUSIO PHARMACEUTICALS, LLC 2007-02-01 US disclosed
US-20070027329-A1 Method for enantioselective hydrogenation of chromenes AUSIO PHARMACEUTICALS, LLC 2007-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116450-A1 METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES HRH3, HRH2, CHD8 RARA 2242/4885RARG 1393/4885RARB 2733/4885
US-20070027329-A1 Method for enantioselective hydrogenation of chromenes HRH3, HRH2, CHD8 RARA 2242/4885RARG 1393/4885RARB 2733/4885
US-20100069653-A1 METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES HRH3, HRH2, CHD8 RARA 2242/4885RARG 1393/4885RARB 2733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.